Cargando…

VTd-PACE and VTd-PACE-like regimens are effective salvage therapies in difficult-to-treat relapsed/refractory multiple myeloma: a single-center experience

Although treatment options for multiple myeloma (MM) are rapidly evolving, there still remain difficult-to-treat situations, especially in relapsed and/or refractory (r/r) disease. When modern therapies are exhausted, or emergency treatment is needed for high tumor burden, classic chemotherapy combi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghandili, Susanne, Alihodzic, Dzenefa, Wiessner, Christian, Bokemeyer, Carsten, Weisel, Katja, Leypoldt, Lisa B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667441/ https://www.ncbi.nlm.nih.gov/pubmed/36383242 http://dx.doi.org/10.1007/s00277-022-05027-y

Ejemplares similares

Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
por: Fouquet, Guillemette, et al.
Publicado: (2014)

Benefits of additional cycles of bortezomib/thalidomide/dexamethasone (VTD) induction therapy compared to four cycles of VTD for newly diagnosed multiple myeloma
por: Lee, Yoo Jin, et al.
Publicado: (2019)

Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching
por: Moreau, Philippe, et al.
Publicado: (2020)

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
por: Del Fabro, V., et al.
Publicado: (2023)

Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosis
por: Srkalovic, Gordan, et al.
Publicado: (2005)

Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible
por: Sonneveld, Pieter, et al.
Publicado: (2020)

Effect of Autologous Stem Cell Transplantation Combined with Modified VTD Regimen on Elderly Patients with Multiple Myeloma and Its Influence on miRNA Cytokines
por: Bai, Zhaoliang, et al.
Publicado: (2022)

VTD-melphalan is well tolerated and results in very high rates of stringent CR and MRD-negative status in multiple myeloma
por: Nadiminti, Kalyan, et al.
Publicado: (2017)

Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD
por: Chim, Chor Sang, et al.
Publicado: (2012)

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
por: Terragna, Carolina, et al.
Publicado: (2015)

Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study
por: Byun, Ja Min, et al.
Publicado: (2023)

CD19+ B Lymphocytes Are Predictive for Anti-Sars-Cov-2 Vaccination Response in Multiple Myeloma Patients
por: Ghandili, Susanne, et al.
Publicado: (2021)

Psychometric Characteristics of Different Versions of Vocal Tract Discomfort (VTD) Scale: A Systematic Review
por: Aghaei, Fateme, et al.
Publicado: (2022)

Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma
por: Ghandili, Susanne, et al.
Publicado: (2021)

Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review
por: Parrondo, Ricardo D., et al.
Publicado: (2020)

Short-course bortezomib-based retreatment for patients with multiple myeloma who had received bortezomib-thalidomide-dexamethasone (VTD) as an initial therapy: A single-center case series
por: MAO, JINGJUE, et al.
Publicado: (2014)

The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan
por: Du, Jeng-Shiun, et al.
Publicado: (2022)

OAB-049: Poor post-vaccination anti-SARS-CoV-2-antibody response in patients with Multiple Myeloma correlates with low CD19+ B-lymphocyte count and anti-CD38 treatment
por: Ghandili, Susanne, et al.
Publicado: (2021)

High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group
por: Hus, Iwona, et al.
Publicado: (2019)

P965: STEM-CELL MOBILIZATION WITH CYCLOPHOSPHAMIDE 4 G/M2 ALLOWS COLLECTION OF HIGH NUMBERS OF CD34+ CELLS AFTER DARA-VTD INDUCTION FOR MULTIPLE MYELOMA
por: Perini, Tommaso, et al.
Publicado: (2023)

Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment
por: Ghandili, Susanne, et al.
Publicado: (2021)

P20 LENALIDOMIDE MAINTENANCE AFTER VTD INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A REAL-LIFE STUDY INCLUDING 389 PATIENTS
por: Barilà, G., et al.
Publicado: (2023)

Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
por: Leypoldt, Lisa B., et al.
Publicado: (2023)

Ventricular pacing: to pace or not to pace
por: Levine, Paul A.
Publicado: (2010)

Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group
por: Grzasko, Norbert, et al.
Publicado: (2021)

A Comparative Outcome Analysis of COVID-19 and Influenza Infection in Patients with Hematological Malignancies
por: Ghandili, Susanne, et al.
Publicado: (2021)

COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress
por: Modemann, Franziska, et al.
Publicado: (2022)

Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
por: Thumallapally, Nishitha, et al.
Publicado: (2016)

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION
por: Valdes, Cesar Rodriguez, et al.
Publicado: (2023)

P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL
por: Leypoldt, L., et al.
Publicado: (2022)

P1079: COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA
por: Ermann, D., et al.
Publicado: (2022)

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
por: Shah, Harsh, et al.
Publicado: (2022)

ECG and Pacing Criteria for Differentiating Conduction System Pacing from Myocardial Pacing
por: Jastrzębski, Marek
Publicado: (2021)

Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma
por: Fotiou, Despina, et al.
Publicado: (2022)

Paced or Non-Paced? Examining an Electrocardiogram Rythm
por: Ferrara, Martha
Publicado: (2017)

Alternative atrial pacing site to improve cardiac function: focus on Bachmann’s bundle pacing
por: Cronin, Edmond M, et al.
Publicado: (2023)

Salvage treatment of relapsed/refractory LCH
por: Seo, Jong Jin
Publicado: (2016)

Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma
por: Ng, M, et al.
Publicado: (2005)

Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults
por: Ju, Hee Young, et al.
Publicado: (2022)

PB2263: TOXICITY PROFILE OF SALVAGE CHEMOTHERAPY REGIMENS IN PATIENTS WITH RELAPSED/ REFRACTORY HODGKIN LYMPHOMA.
por: Zahra, Kmira, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f56sg3j20np01ltvukvpukv9rb